Patents Assigned to InterVet, Inc.
  • Publication number: 20200206340
    Abstract: The present invention pertains to a vaccine comprising an ORF2 encoded protein of porcine circo virus 2 (PCV2) and a pharmaceutically acceptable carrier, for use in a method to protect a pig against an infection with porcine circo virus type 2 by administering the vaccine to the pig, wherein the vaccine comprises less than 20 ?g per dose of the ORF2 encoded protein, the protein being of a porcine circo virus of genotype 2b.
    Type: Application
    Filed: August 2, 2018
    Publication date: July 2, 2020
    Applicant: Intervet Inc.
    Inventors: Melanie SNO, Erik COX, Ruud Philip Antoon Maria SEGERS
  • Publication number: 20200206336
    Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting piglets having maternally derived anti-Streptococcus suis antibodies against Streptococcus suis, by administering the vaccine to the piglets at an age of at most 28 days, preferably before the piglets are weaned.
    Type: Application
    Filed: August 2, 2018
    Publication date: July 2, 2020
    Applicant: Intervet Inc.
    Inventor: Antonius Arnoldus Christiaan JACOBS
  • Patent number: 10689612
    Abstract: The invention pertains to a method to purify coccidial oocysts having dimensions between Dmin and Dmax from faeces comprising the steps of collecting the faeces containing the coccidial oocysts from host animals, diluting the faeces in an aqueous medium, separating a coarse fraction comprising macroscopic particulate matter from the diluted faeces and collecting an aqueous fraction containing the oocysts, characterised in that the method further comprises sieving the aqueous fraction over a first sieve deck having mesh openings to let the oocysts pass, to obtain an aqueous filtrate comprising the oocysts and a first residue comprising particles larger than the oocysts, and sieving the aqueous filtrate over a second sieve deck having mesh openings to obstruct passing of the oocysts through this sieve deck, to obtain a second residue comprising the purified oocysts and a waist filtrate comprising particles smaller than the oocysts.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: June 23, 2020
    Assignee: Intervet Inc.
    Inventors: Koen Gevers, Theodorus Petrus Maria Schetters
  • Patent number: 10653675
    Abstract: The present invention relates to methods of treating or preventing arthropod infestations of poultry animals and methods of controlling arthropod infestations in poultry animal's environment by administering an isoxazoline compound of formula (I) via drinking water.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: May 19, 2020
    Assignee: Intervet Inc.
    Inventors: Anja Regina Heckeroth, Hartmut Zoller, Annie Flochlay-Sigognault, Bruno Huyghe
  • Publication number: 20200115367
    Abstract: The instant invention provides compounds of formula I which are selective JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as atopic dermatitis, arthritis, and cancer.
    Type: Application
    Filed: December 13, 2017
    Publication date: April 16, 2020
    Applicant: Intervet Inc.
    Inventors: Peter H. Fuller, Jason Brubaker, Jonathan R. Young
  • Publication number: 20200109212
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Application
    Filed: December 18, 2019
    Publication date: April 9, 2020
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Publication number: 20200085779
    Abstract: The present invention provides compounds for use in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).
    Type: Application
    Filed: December 22, 2017
    Publication date: March 19, 2020
    Applicant: Intervet Inc.
    Inventors: Thorsten Meyer, Ralf Warrass, Joachim Ullrich, Michael Berger, Michael Linder
  • Publication number: 20200085935
    Abstract: The present invention relates to a combination vaccine for swine, comprising non-replicating antigen from porcine circovirus type 2 (PCV2), and live porcine reproductive and respiratory syndrome virus (PRRSV); the combination vaccine is formulated as an oil-in-water emulsion, and is adjuvated with squalane and vitamin E-acetate. This combination vaccine was found to be immunologically effective against all pathogens: PCV2, and PRRSV.
    Type: Application
    Filed: December 22, 2017
    Publication date: March 19, 2020
    Applicant: Intervet Inc.
    Inventors: Theodorus Jansen, Maarten Hendrik Witvliet
  • Patent number: 10588729
    Abstract: An apparatus for injecting a liquid into live animals, comprising a cradle plate (18) having a cradle (24) for accommodating at least a part of an animal, sensors (20-1, 20-2, 20-3) for detecting a force acting upon the cradle plate, an injection mechanism (16) for injecting liquid into the animal, and a control unit (38) for triggering the injection mechanism (16) in response to signals received from the sensors, wherein at least three sensors (20-1-, 20-2, 20-3) are arranged for measuring forces with which the cradle plate (18) is pressed against a base (12) in at least three non-aligned positions, and the control unit (38) is adapted to trigger the injection mechanism (16) when the forces measured by the sensors are distributed according to a predetermined pattern.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: March 17, 2020
    Assignee: Intervet Inc.
    Inventor: Mathias Theodorus Maria Moons
  • Publication number: 20200080981
    Abstract: The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.
    Type: Application
    Filed: October 31, 2019
    Publication date: March 12, 2020
    Applicant: Intervet Inc.
    Inventors: Michelle Allen, Mark Garrett, Urs Peter Bruderer, Martinus Antonius Johannes Thijssen
  • Patent number: 10575776
    Abstract: The invention includes a system and method for predicting the performance of production animals by analysis of heart and lung sounds to determine likelihoods the animals will develop BRD or other diseases or ailments. Vital signs of animals are recorded during an adrenergic sympathetic “flight or fight” situation. A cardio-pulmonary rate ratio is determined for each animal by dividing a normalized adjusted heart rate value by a normalized adjusted respiratory value. From the ratios calculated for each animal in a group, a ratio range is established. Ratio values at a lower end of the ratio range indicate higher relative respiration rates and poor lung performance due to disease. Ratio values at an upper end of the range may indicate low cardiac output and an inability to tolerate rapid weight gain. Ratio values at either end of the range may indicate compromised cardio-pulmonary function.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: March 3, 2020
    Assignee: INTERVET INC.
    Inventor: Kurt Brattain
  • Patent number: 10568954
    Abstract: The present invention describes a process for the preparation of an antigen composition, which antigen composition can be used to prepare a ready-to-use vaccine for swine, for preventing or reducing infection by M. hyo or PCV2 and associated signs of disease. The process is characterised in that it comprises a step of admixing a PCV2 antigen to a pre-formed antigen/adjuvant complex of an M. hyo antigen adsorbed to an Aluminium-hydroxide adjuvant. This way a PCV2/M. hyo combination vaccine can be prepared that is highly effective already after a single administration, against infection and disease by M. hyo and PCV2 either when in single or in combined infections. Also the vaccine has very good safety upon administration, is ready-to-use, and is economically feasible.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: February 25, 2020
    Assignee: Intervet Inc.
    Inventors: Maarten Hendrik Witvliet, Theodorus Jansen, Huchappa Gowda Jayappa
  • Patent number: 10562834
    Abstract: A process to prepare a compound of Formula (I) wherein R3, R4 and R5 are each selected independently from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxyl, and wherein the alkyl, alkenyl, alkynyl, and alkoxyl may be optionally substituted with one or more halogen, alkyl, alkenyl, alkynyl, and alkoxyl.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: February 18, 2020
    Assignee: Intervet Inc.
    Inventors: Michael Berger, Stephan Veit, Hans Peter Niedermann, Tobias Kappesser, Alfred Stutz
  • Publication number: 20200046825
    Abstract: The present invention pertains to a combination of a first vaccine comprising non-replicating immunogen of porcine circo virus type 2 (PCV2) and non-replicating immunogen of Mycoplasma hyopneumoniae, and a second vaccine comprising live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating an animal against an infection with porcine circovirus type 2, an infection with Mycoplasma hyopneumoniae and an infection with PRRS virus, by associated non-mixed administration of the first vaccine and the second vaccine to the animal. The invention also pertains to a kit-of-parts comprising the first and second vaccine and to a method of protecting an animal against such infections using these vaccines.
    Type: Application
    Filed: April 12, 2018
    Publication date: February 13, 2020
    Applicant: Intervet Inc.
    Inventors: Maarten Hendrik WITVLIET, Erwin van den BORN, Melanie SNO, Antonius Arnoldus Christiaan JACOBS
  • Patent number: 10555998
    Abstract: The present invention relates to equine influenza virus (EIV) isolates that when administered in vaccines to equine provide protection against currently emerging EIV strains in the U.S. The present invention also relates to inactivated EIV isolates. In addition, the present invention also relates to safe and efficacious vaccines that comprise the EIV isolates, as well as to corresponding subunit vaccines. The present invention further relates to methods of administering such safe and efficacious vaccines to equine.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: February 11, 2020
    Assignee: Intervet Inc.
    Inventors: Zhisong Qiao, Catherine M. Peters, Zhuyan Guo, Wendy Vaala, Craig Barnett
  • Patent number: 10550194
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L1 that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: February 4, 2020
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Publication number: 20200023128
    Abstract: A needle-less injector having a housing comprising two or more separate chambers defined within said injector for containing liquid to be injected wherein each chamber comprises 1) a liquid outlet positioned at the front end of the injector; and 2) a dispensing member in contact with the liquid in said chambers and movable in a first direction to reduce the volume of said chamber to cause the liquid contained therein to be expelled through said liquid outlet, wherein the needleless injector further comprising a drive means for actuating said injector, wherein the distance between the liquid outlet for each of said chambers is at least 20 mm.
    Type: Application
    Filed: December 21, 2017
    Publication date: January 23, 2020
    Applicant: Intervet Inc.
    Inventors: Vicky Fachinger, Erik Cox
  • Publication number: 20200000720
    Abstract: This invention is directed to a pharmaceutical composition for drinking water administration comprising isoxazoline compounds of formula (I) and a polysorbate surfactant and diethylene glycol monoethyl ether (transcutol); and the use of the composition to treat or prevent parasite infestations of animals.
    Type: Application
    Filed: September 13, 2019
    Publication date: January 2, 2020
    Applicant: Intervet Inc.
    Inventors: Anne Lehay, Annie Flochlay-Sigognault
  • Publication number: 20200000718
    Abstract: A solid oral pharmaceutical composition for delivery of a pharmaceutically acceptable active ingredient to an animal where the composition comprises an isoxazoline compound, a solvent and an excipient, a process for the manufacture of such solid oral pharmaceutical composition and a method of controlling a parasite infection administering such solid oral pharmaceutical composition.
    Type: Application
    Filed: July 11, 2019
    Publication date: January 2, 2020
    Applicant: Intervet Inc.
    Inventors: Keith Freehauf, Niki Waldron, Jürgen Lutz, Frank Guerino
  • Patent number: 10512685
    Abstract: The present invention relates to a vaccine comprising Open Reading Frame 2 (ORF2) protein of Swine Hepatitis E virus (HEV) and a pharmaceutically acceptable carrier, for use in the protection of anti-HEV MDA-positive piglets against HEV fecal shedding.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: December 24, 2019
    Assignee: Intervet Inc.
    Inventors: Paul Vermeij, Ad Groof De, Carla Christina Schrier, Wannes Vogels